Clinical trial
Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat…
NCT00311129 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00311129 |
|---|---|
| Title | Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL |
| Official title | A Multicenter Study to Assess the Antitumor Effect and Safety of Fludarabine Phosphate Tablet (SH T 586) in Combination With Rituximab Administered in 6 Treatment Cycles (1 Treatment Cycle: Rituximab 375 mg/m2 iv on Day 1 Along With 5-Consecutive Day Oral Dosing of SH T 586 40 mg/m2/Day From Day 1… |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Low-Grade |
| Intervention type | Drug |
| Interventions | Fludarabine Phosphate (Fludara), Rituximab |
| Enrollment | 41 |
| Start date | Dec 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Apr 5, 2006 |
| Last update posted | Dec 4, 2013 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: